Modus Therapeutics Holding

0.48 SEK

-2.85 %

Less than 1K followers

MODTX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2.85 %
+6.46 %
+56.21 %
+57.24 %
+22.56 %
-15.21 %
-52.26 %
-
-76.91 %

Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.

Read more
Market cap
71.08M SEK
Turnover
240.65K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/5
2026

Interim report Q1'26

28/5
2026

General meeting '26

26/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.